Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Extended interval BNT162b2 vaccination enhances peak antibody generation in older people

View ORCID ProfileH Parry, R Bruton, C Stephens, K Brown, G Amirthalingam, B Hallis, A Otter, J Zuo, P Moss
doi: https://doi.org/10.1101/2021.05.15.21257017
H Parry
1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for H Parry
R Bruton
1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Stephens
1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Brown
2National infection Service, Public Health England, Colindale, London NW9 5EQ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Amirthalingam
2National infection Service, Public Health England, Colindale, London NW9 5EQ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Hallis
3National infection Service, Public Health England, Porton Down, Salisbury, SP4 OJG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Otter
3National infection Service, Public Health England, Porton Down, Salisbury, SP4 OJG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Zuo
1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Moss
1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: p.moss@bham.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives To assess the relative immunogenicity of standard or extended interval BNT162b2 vaccination.

Design Population based cohort study comparing immune responses 2 weeks after the second vaccine, with appropriate time-matched samples in participants who received standard or extended interval double vaccination.

Setting Primary care networks, Birmingham, UK. December 2020 to April 2021.

Participants 172 people aged over 80 years of age. All donors received the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a standard 3 week interval between doses or an extended interval schedule.

Main outcome measures Peak quantitative spike-specific antibody and cellular immune responses.

Results In donors without evidence of previous infection the peak antibody response was 3.5-fold higher in donors who had undergone delayed interval vaccination. Cellular immune responses were 3.6-fold lower.

Conclusion Peak antibody responses after the second BNT162b2 vaccine are markedly enhanced in older people when this is delayed to 12 weeks although cellular responses are lower. Extended interval vaccination may therefore offer the potential to enhance and extend humoral immunity. Further follow up is now required to assess long term immunity and clinical protection.

What is already known on this topic The BNT162b2 vaccine is highly effective against Covid-19 infection and was delivered with a 3-week time interval in registration studies. However, this interval has been extended in many countries in order to extend population coverage with a single vaccine. It is not known how immune responses after the second dose are influenced by delaying the second vaccine.

What this study adds We provide the first assessment of immune responses in the first 14 weeks after standard or extended interval BNT162b2 vaccination and show that delaying the second dose acts to strongly boost the peak antibody response in older people. The extended interval vaccination may offer a longer period of clinical protection. This information will be of value in optimizing vaccine regimens and help guide guide vaccination policies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the UK Coronavirus Immunology Consortium (UK-CIC) funded by DHSC/UKRI and the National Core Studies Immunity programme. Ethical Approval: The work was performed under the CIA UPH IRAS approval (REC 20\NW\0240) and conducted according to the Declaration of Helsinki and good clinical practice.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was obtained from North West Preston Research Ethics Committee with favourable outcome and approval (REC 20\NW\0240).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Authors agree to share the anonymised raw data for this study once published.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 17, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Extended interval BNT162b2 vaccination enhances peak antibody generation in older people
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Extended interval BNT162b2 vaccination enhances peak antibody generation in older people
H Parry, R Bruton, C Stephens, K Brown, G Amirthalingam, B Hallis, A Otter, J Zuo, P Moss
medRxiv 2021.05.15.21257017; doi: https://doi.org/10.1101/2021.05.15.21257017
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Extended interval BNT162b2 vaccination enhances peak antibody generation in older people
H Parry, R Bruton, C Stephens, K Brown, G Amirthalingam, B Hallis, A Otter, J Zuo, P Moss
medRxiv 2021.05.15.21257017; doi: https://doi.org/10.1101/2021.05.15.21257017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1774)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10826)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2963)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1935)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (294)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12530)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2815)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (258)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (340)
  • Psychiatry and Clinical Psychology (2650)
  • Public and Global Health (5387)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (293)
  • Sports Medicine (279)
  • Surgery (328)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (127)